Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/6911
DC FieldValueLanguage
dc.contributor.authorSalehi, Bahareen_US
dc.contributor.authorSelamoglu, Zelihaen_US
dc.contributor.authorMileski, Ksenijaen_US
dc.contributor.authorPezzani, Raffaeleen_US
dc.contributor.authorRedaelli, Marcoen_US
dc.contributor.authorCho, William Cen_US
dc.contributor.authorKobarfard, Farzaden_US
dc.contributor.authorRajabi, Sadeghen_US
dc.contributor.authorMartorell, Miquelen_US
dc.contributor.authorKumar, Pradeepen_US
dc.contributor.authorMartins, Natáliaen_US
dc.contributor.authorSubhra Santra, Tuhinen_US
dc.contributor.authorSharifi-Rad, Javaden_US
dc.date.accessioned2023-12-04T08:31:36Z-
dc.date.available2023-12-04T08:31:36Z-
dc.date.issued2019-11-23-
dc.identifier.issn2218-273X-
dc.identifier.urihttps://biore.bio.bg.ac.rs/handle/123456789/6911-
dc.description.abstractCancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications.en_US
dc.language.isoenen_US
dc.relation.ispartofBiomoleculesen_US
dc.subjectDepoCyten_US
dc.subjectcancer therapyen_US
dc.subjectchemotherapyen_US
dc.subjectliposomal ara-Cen_US
dc.subjectliposomal cytarabineen_US
dc.subjectliposomal cytosine arabinosideen_US
dc.titleLiposomal Cytarabine as Cancer Therapy: From Chemistry to Medicineen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.3390/biom9120773-
dc.identifier.pmid31771220-
dc.identifier.scopus2-s2.0-85075438624-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85075438624-
dc.description.startpage773en_US
dc.description.volume9en_US
dc.description.issue12en_US
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptChair of Plant Morphology and Systematics-
crisitem.author.orcid0000-0001-6116-5384-
Appears in Collections:Journal Article
Show simple item record

SCOPUSTM   
Citations

52
checked on Nov 17, 2024

Page view(s)

10
checked on Nov 20, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.